Treatment options for patients with severe gastroparesis

Gut

Volumn 56, Issue 6, 2007, Pages 877-883

  Abrahamsson, Hasse ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; BOTULINUM TOXIN; DOPAMINE RECEPTOR BLOCKING AGENT; MACROLIDE; SEROTONIN 4 AGONIST;

ARTICLE; BREATH ANALYSIS; CLINICAL FEATURE; COST; ELECTROSTIMULATION; GASTROSCOPY; HUMAN; NUTRITIONAL ASSESSMENT; PRIORITY JOURNAL; SCINTIGRAPHY; STOMACH EMPTYING; STOMACH PARESIS;

BOTULINUM TOXINS; DOPAMINE ANTAGONISTS; ELECTRIC STIMULATION THERAPY; GASTROINTESTINAL AGENTS; GASTROPARESIS; HUMANS; MACROLIDES;

EID: 34249786863     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.078121     Document Type: Article

References (63)

1. Tougas G, Eaker E, Abell T, et al. Assessment of gastric emptying using a low fat meal: establishment of international control values. Am J Gastroenterol 2000;95:1456-62.
2. Grybäck P, Hermansson G, Lyrenäs E, et al. Nationwide standardisation and evaluation of scintigraphic gastric emptying: reference values and comparisons between subgroups in a multicentre trial. Eur J Nucl Med 2000;27:647-55.
3. Strid H, Simrén M, Stotzer P-O, et al. Delay in gastric emptying in patients with chronic renal failure. Scand J Gastroenterol 2004;39:516-20.
4. Maes BD, Ghoos YF, Hiele MI, et al. Gastric emptying rate of solids in patients with nonulcer dyspepsia. Dig Dis Sci 1997;42:1158-62.
5. Horowitz M, Wishart JM, Jones KL, et al. Gastric emptying in diabetes: an overview. Diabet Med 1996;13(Suppl 5):S16-22.
6. Bityutskiy LP, Soykan I, McCallum RW. Viral gastroparesis: a subgroup of idiopathic gastroparesis - clinical characteristics and long-term outcomes. Am J Gastroenterol 1997;92:1501-4.
7. Soykan I, Sivri B, Sarosiek I, et al. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig Dis Sci 1998;43:2398-404.
8. Caballero-Plasencia AM, Muros-Navarro MC, Martin-Ruiz JL, et al. Dyspeptic symptoms and gastric emptying of solids in patients with functional dyspepsia. Role of Helicobacter pylori infection. Scand J Gastroenterol 1995;30:745-51.
9. Schoonjans R, Van VB, Vandamme W, et al. Dyspepsia and gastroparesis in chronic renal failure: the role of Helicobacter pylori. Clin Nephrol 2002;57:201-7.
10. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004;12:1239-55.
11. Jones KL, Russo A, Stevens JE, et al. Predictors of delayed gastric emptying in diabetes. Diabetes Care 2001;24:1264-9.
12. Stanghellini V, Tosetti C, Paternic A, et al. Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology 1996;110:1036-42.
13. Sarnelli G, Caenepeel P, Geypens B, et al. Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol 2003;98:783-8.
14. Janssens J, Peeters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med 1990;322:1028-31.
15. Richards RD, Davenport K, McCallum RW. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol 1993;88:203-7.
16. Camilleri M. The current role of erythromycin in the clinical management of gastric emptying disorders. Am J Gastroenterol 1993;88:169-71.
17. Sturm A, Holtmann G, Goebell H, et al. Prokinetics in patients with gastroparesis: a systematic analysis. Digestion 1999;60:422-7.
18. Talley NJ, Verlinden M, Snape W, et al. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2000;14:1653-61.
19. Talley NJ, Verlinden M, Geenen DJ, et al. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial. Gut 2001;49:395-401.
20. Russo A, Stevens JE, Giles N, et al. Effect of the motilin agonist KC 11458 on gastric emptying in diabetic gastroparesis. Aliment Pharmacol Ther 2004;20:333-8.
21. Murray CD, Martin NM, Patterson M, et al. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut 2005;54:1693-8.
22. Tack J, Depoortere I, Bisschops R, et al. Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. Aliment Pharmacol Ther 2005;22:847-53.
23. Horowitz M, Harding PE, Chatterton BE, et al. Acute and chronic effects of domperidone on gastric emptying in diabetic autonomic neuropathy. Dig Dis Sci 1985;30:1-9.
24. Mansi C, Savarino V, Vigneri S, et al. Gastrokinetic effects of levosulpiride in dyspeptic patients with diabetic gastroparesis. Am J Gastroenterol 1995;90:1989-93.
25. Mansi C, Borro P, Giacomini M, et al. Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis. Aliment Pharmacol Ther 2000;14:561-9.
26. Mearin F, Rodrigo L, Perez-Mota A, et al. Levosulpiride and cisapride in the treatment of dysmotility-like functional dyspepsia: a randomized, double-masked trial. Clin Gastroenterol Hepatol 2004;2:301-8.
27. Degen L, Petrig C, Studer D, et al. Effect of tegaserod on gut transit in male and female subjects. Neurogastroenterol Motil 2005;17:821-6.
28. Bromer MQ, Friedenberg F, Miller LS, et al. Endoscopic pyloric injection of botulinum toxin A for the treatment of refractory gastroparesis. Gastrointest Endosc 2005;61:833-9.
29. Arts J, Caenepeel P, Holvoet L, et al. A sham-controlled study of intrapyloric injection of botulinum toxin in gastroparesis. Gastroenterology 2005;128(Suppl 2):A-81.
30. Familione B, Abell T, Nemoto D, et al. Efficacy of electrical stimulation at frequencies higher than basal rate in canine stomach. Dig Dis Sci 1997;42:892-7.
31. Familione B, Abell T, Voeller G, et al. Electrical stimulation at a frequency higher than basal rate in human stomach. Dig Dis Sci 1997;42:885-91.
32. Lönroth H, Abrahamsson H. Laparoscopic and open placement of electronic implants for gastric electrical stimulation: technique and results. Minim Invasive Ther Allied Technol 2004;13:336-9.
33. Al-Juburi A, Granger S, Barnes J, et al. Laparoscopy shortens length of stay in patients with gastric electrical stimulators. J Soc Laparoendosc Surg 2005;9:305-10.
34. Abell T, Van Cutsem E, Abrahamsson H, et al. Gastric electrical stimulation in intractable symptomatic gastroparesis. Digestion 2002;66:204-12.
35. Abell T, McCallum R, Hocking M, et al. Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology 2003;125:421-8.
36. Forster J, Sarosiek I, Lin Z, et al. Further experience with gastric stimulation to treat drug refractory gastroparesis. Am J Surg 2003;186:690-5.
37. Abell T, Lou J, Tabbaa M, et al. Gastric electrical stimulation for gastroparesis improves nutritional parameters at short, intermediate, and long-term follow-up. J Parenter Enteral Nutr 2003;27:277-81.
38. Lin Z, Forster J, Sarosiek I, et al. Treatment of diabetic gastroparesis by high-frequency gastric electrical stimulation. Diabetes Care 2004;27:1071-6.
39. van der Voort IR, Becker JC, Dietl KH, et al. Gastric electrical stimulation results in improved metabolic control in diabetic patients suffering from gastroparesis. Exp Clin Endocrinol Diabetes 2005;113:38-42.
40. Lin Z, McElhinney C, Sarosiek I, et al. Chronic gastric electrical stimulation for gastroparesis reduces the use of prokinetic and/or antiemetic medications and the need for hospitalizations. Dig Dis Sci 2005;50:1328-34.
41. Mason RJ, Lipham J, Eckerling G, et al. Gastric electrical stimulation: an alternative surgical therapy for patients with gastroparesis. Arch Surg 2005;140:841-6.
42. McCallum R, Lin Z, Wetzel P, et al. Clinical response to gastric electrical stimulation in patients with postsurgical gastroparesis. Clin Gastroenterol Hepatol 2005;3:49-54.
43. Oubre B, Luo J, Al-Juburi A, et al. Pilot study on gastric electrical stimulation on surgery-associated gastroparesis: long-term outcome. South Med J 2005;8:693-7.
44. Andersson S, Lönroth H, Simren M, et al. Gastric electrical stimulation for intractable vomiting in patients with chronic intestinal pseudoobstruction. Neurogastroenterol Motil 2006;18:823-30.
45. McCallum RW, Lin Z, Sarosiek I, et al. Is high-frequency gastric electrical stimulation effective in patients with chronic nausea and vomiting and a normal gastric emptying? Gastroenterology 2006;130(Suppl 2):A-511.
46. Abrahamsson H, Andersson S, Ringström G, et al. Temporary percutaneous gastric electrical stimulation (GES). A new technique to test response to GES. Neurogastroenterol Motil 2006;18:668.
47. Gourcerol G, Leblanc I, Leroi AM, et al. Gastric electrical stimulation in medically refractory nausea and vomiting. Neurogastroenterol Motil 2006;18:741.
48. Cutts TF, Luo J, Starkebaum W, et al. Is gastric electrical stimulation superior to standard pharmacologic therapy in improving GI symptoms, healthcare resources, and long-term health care benefits? Neurogastroenterol Motil 2005;17:35-43.
49. Lin Z, Sarosiek I, Forster J, et al. Predictors of symptom non-responders to high-frequency gastric electrical stimulation for refractory gastroparesis. Gastroenterology 2006;130(Suppl 2):A-246.
50. Maranki JL, Lytes V, Merilahn JE, et al. Predictive factors for clinical improvement with Enterra gastric electrical stimulation treatment for refractory gastroparesis. Gastroenterology 2006;130(Suppl 2):A-43.
51. Abidi N, Starkebaum WL, Abell TL. An energy algorithm improves symptoms in some patients with gastroparesis and treated with gastric electrical stimulation. Neurogastroenterol Motil 2006;18:334-8.
52. Ayinala S, Batista O, Goyal A, et al. Temporary gastric electrical stimulation with orally or PEG-placed electrodes in patients with drug refractory gastroparesis. Gastrointest Endosc 2005;61:455-61.
53. Elfvin A, Andersson S, Abrahamsson H, et al. Percutaneous implantation of gastric electrodes - a novel technique applied in animals and in patients. Neurogastroenterol Motil 2007;19:103-9.
54. Petrakis IE, Vrachassotakis N, Sciacca V, et al. Hyperglycaemia attenuates erythromycin-induced acceleration of solid-phase gastric emptying in idiopathic and diabetic gastroparesis. Scand J Gastroenterol 1999;34:396-403.
55. Jones KL, Berry M, Kong MF, et al. Hyperglycemia attenuates the gastrokinetic effect of erythromycin and affects the perception of postprandial hunger in normal subjects. Diabetes Care 1999;22:339-44.
56. Rayner CK, Su YC, Doran SM, et al. The stimulation of antral motility by erythromycin is attenuated by hyperglycemia. Am J Gastroenterol 2000;95:2233-41.
57. Petrakis IE, Kogerakis N, Prokopakis G, et al. Hyperglycemia attenuates erythromycin-induced acceleration of liquid-phase gastric emptying of hypertonic liquids in healthy subjects. Dig Dis Sci 2002;47:67-72.
58. Horowitz M, Jones KL, Harding PE, et al. Relationship between the effects of cisapride on gastric emptying and plasma glucose concentrations in diabetic gastroparesis. Digestion 2002;65:41-6.
59. Petrakis IE, Kogerakis N, Vrachassotakis N, et al. Hyperglycemia attenuates erythromycin-induced acceleration of solid-phase gastric emptying in healthy subjects. Abdom Imaging 2002;27:309- 14.
60. Braden B, Enghofer M, Schaub M, et al. Long-term cisapride treatment improves diabetic gastroparesis but not glycaemic control. Aliment Pharmacol Ther 2002;16:1341-6.
61. Lehmann R, Honegger RA, Feinle C, et al. Glucose control is not improved by accelerating gastric emptying in patients with type 1 diabetes mellitus and gastroparesis. A pilot study with cisapride as a model drug. Exp Clin Endocrinol Diabetes 2003;111:255-61.
62. Melga P, Mansi C, Ciuchi E, et al. Chronic administration of levosulpiride and glycemic control in IDDM patients with gastroparesis. Diabetes Care 1997;20:55-8.
63. Gentilcore D, O'Donovan D, Jones KL, et al. Nutrition therapy for diabetic gastroparesis. Curr Diabetes Rep 2003;3:418-26.